The earlier studies conducted by Zhang and their colleagues explicated that fisetin markedly enhanced the sensitivity of erlotinib‐resistant lung cancer cells HCC827 to erlotinib via suppressing the aberrant activation of MAPK and AKT signaling pathways resulted from AXL suppression (Klimaszewska‐Wisniewska et al., 2016; Zhang et al., 2016). This evidence concerns the gene AXL and lung carcinoma.